Literature DB >> 16574318

Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.

Dorota Kostrzewa-Nowak1, Mark J I Paine, Anna Korytowska, Katarzyna Serwatka, Sylwia Piotrowska, C Roland Wolf, Jolanta Tarasiuk.   

Abstract

The aim of this study was to examine the role of reductive activation of mitoxantrone (MX) by human liver NADPH cytochrome P450 reductase (CPR) in increasing its ability to inhibit the growth of human promyelocytic sensitive leukaemia HL60 cell line as well as its MDR sublines exhibiting two different phenotypes of MDR related to the overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX). Our assays showed that the reduction of MX by exogenously added CPR in the presence of low NADPH concentration had no effect in increasing its ability to inhibit the growth of sensitive and MDR tumour cells. In contrast, an important increase in antiproliferative activity of MX after its reductive activation by CPR at high NADPH concentration was observed against HL60/VINC as well as HL60/DOX cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574318     DOI: 10.1016/j.canlet.2006.01.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.

Authors:  Michel Kranendonk; Christopher C Marohnic; Satya P Panda; Maria Paula Duarte; José Santos Oliveira; Bettie Sue Siler Masters; José Rueff
Journal:  Arch Biochem Biophys       Date:  2008-04-20       Impact factor: 4.013

2.  Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells.

Authors:  Amit Wani; Galbokka H Layan Savithra; Ayat Abyad; Shrey Kanvinde; Jing Li; Stephanie Brock; David Oupický
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.